Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E E4 Non-Carriers
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Bapineuzumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Pfizer; Wyeth
- 07 Apr 2022 This trial has been completed in Slovakia (Global end date: 27-11-2012), according to European Clinical Trials Database record.
- 02 Apr 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 26 Mar 2022 This trial has been completed in Belgium (End Date: 27 Nov 2012), according to European Clinical Trials Database record.